GENETIC STATUS OF PATIENTS WITH OCCLUSAL-STENOTIC LESIONS OF THE AORTO-ILIOFEMOROUS SEGMENT AND ITS INFLUENCE ON THE OUTCOMES OF REVASCULARIZING INTERVENTIONS

1. Gorohova VG, Kuznecova EE, Kuril‘skaja AG. Opredelenie faktorov riska ateroskleroza [Determination of risk factors for atherosclerosis]. Uspehi sovremennogo estestvoznanija [Advances in modern natural science]. 2004; 6: 105–106.

2. Klenkova NA, Kapustin SI, Saltykova NB. Osobennosti allel‘nogo polimorfizma genov metabolizma gomocisteina i folatov u bol‘nyh s aterosklerozom arterij nizhnih konechnostej [Features of allelic polymorphism of homocysteine and folate metabolism genes in patients with atherosclerosis of arteries of the lower extremities]. Vestn. hirurgii im. I. I. Grekova [Vestn. of surgery I. I. Grekov]. 2009; 168 (6): 41–44.

3. Naumov AV. Gomocistein. Mediko-biologicheskie problem [Homocysteine. Biomedical problems]. Minsk: Professional‘nye izdanija; 2013. 312 p. (Russian).

4. Panasiuk OV, Mogilevec EV, Naumov AV, Kopyckij AV. Analiz vlijanija revaskuljarizacii na pul aminokislot i opredelenija ego roli v razvitii posleoperacionnyhoslozhnenij u pacientov s zabolevanijami arterij nizhnih konechnostej [Analysis of the effect of revascularization on the amino acid pool and determination of its role in the development of postoperative complications among the patients with lower limb arterial diseases]. Voennaja medicina [Military medicine]. 2022; 17 (2): 63-74. doi.org/10.51922/2074-5044.2022.2.63

5. Panasyuk OV. Mogilevec EV, Naumov AV. Vlijanie gipergomocisteinemii na razvitie obliterirujushhego ateroskleroza arterij nizhnih konechnostej [Influence of hyperhomocysteinemia on the development of obliterating atherosclerosis of the arteries of the lower extremities]. Zdravoohranenie [Healthcare]. 2020; 875 (2): 30 – 35.

6. Panasyuk OV. Mogilevec EV, Naumov AV. Vozmozhnosti holina i ego metabolita v korrekcii gipergomocisteinemii snizhenii razvitija serdechno-sosudistoj patologii [Possibilities of choline and its metabolite in the correction of hyperhomocysteinemia and the reduction in the development of cardiovascular pathology]. Neotlozhnaja kardiologija i kardiovaskuljarnye riski [Emergency Cardiology and Cardiovascular Risks]. 2020; 4 (1): 904 – 908.

7. Panasiuk OV, Mogilevec EV, Kopyckij AV. Prognozirovanie ishodov infraingvinalnyh revaskuljarizirujushhih operacij u pacientov s zabolevanijami arterij nizhnih konechnostej [Results prognosis for revascularization surgeries below the inguinal ligament on patients with lower extremity arterial disease]. Nauka i innovacii [Science and innovation]. 2022; 15 (12): 68-72. doi.org/10.29235/1818-9857-2022-12-68-72.

8. Hamidi AK, Radfar M, Amoli MM. Association between MTHFR variant and diabetic neuropathy. Pharmacol Rep. 2018; 70 (1): 1–5. doi.org/10.1016/j.pharep.2017.04.017.

9. Hosseini M. Role of polymorphism of methyltet)rahydrofolate-homocysteine methyltransferase (MTR) A2756G and breast cancer risk. Pol J Pathol. 2013; 64 (3): 191–195. doi.org/10.5114/pjp.2013.38138.

10. Joachim E, Goldenberg NA, Bernard TJ The methylenetetrahydrofolate reductase polymorphism (MTHFR c.677C > T) and elevated plasma homocysteine levels in a U. S. pediatric population with incident thromboembolism. Thromb Res. 2013; 132 (2): 170–174.doi.org/10.1016/j.thromres.2013.06.005.

11. Khandanpour N, Willis G, Meyer FJ. Peripheral arterial disease and methylenetetrahydrofolate reductase (MTHFR) C677T mutations: A case-control study and meta-analysis. J Vasc Surg. 2009; 49 (3): 711-718. doi.org/10.1016/j.jvs.2008.10.004.

12. Mahesh M, Cheng G, Khalighi K. Association of Methylenetetrahydrofolate Reductase (MTHFR) A1298C Polymorphism with Lower High-Density Lipoprotein Cholesterol Level. Ann Clin Lab Sci. 2019; 49 (2): 232–236. doi.org/10.1053/j.semvascsurg.2009.10.003.

13. Marini NJ, Gin J, Ziegle J. The prevalence of folate-remedial MTHFR enzyme variants in humans. Proc Natl Acad Sci USA. 2008; 105 (23): 8055–8060. doi.org/10.1073/pnas.0802813105.

14. Mialovytska O, Nebor Y. Analysis of relationship between polymorphism of MTHFR (C677T), MTHFR (A1298C), MTR (A2756G) genes in the development of ischemic stroke in young patients. Georgian Med News. 2021; 319 (10): 87–92.

15. Ponti G, Pastorino L, Manfredini M. COVID-19 spreading across world correlates with C677T allele of the methylenetetrahydrofolate reductase (MTHFR) gene prevalence. J Clin Lab Anal. 2021; 35 (7): 1-7. doi.org/10.1002/jcla.23798.

16. Rai V, Yadav U, Kumar P, Yadav S. K. Analysis of methionine synthase reductase polymorphism (A66G) in Indian Muslim population. Indian J Hum Genet. 2013; 19 (2): 183–187. doi.org/10.4103/0971-6866.116123.

17. Townsend N, Wilson L, Bhatnagar P. Cardiovascular disease in Europe: epidemiological update. Eur Heart J. 2016; 37 (42): 3232-3245. doi.org/10.1093/eurheartj/ehu299.